Mood disorders: depression, bipolar; neurobiology and cognitive models
Anchor (Master): Beck, A. T. — Cognitive Therapy and the Emotional Disorders (1976)
Intuition Beginner
Depression is more than ordinary sadness. Sadness fades; depression persists. Major depressive disorder involves at least two weeks of pervasive low mood or a loss of interest in nearly all activities. Alongside this, people experience symptoms such as fatigue, disrupted sleep, appetite and weight changes, difficulty concentrating, feelings of worthlessness or guilt, and sometimes thoughts of death [Myers and DeWall 2021].
Depression is not rare. It affects roughly one in six people over a lifetime, and the World Health Organization ranks it as the leading cause of disability worldwide. It appears in every society studied, though its symptoms surface differently across cultures. In many East Asian and African contexts, depression more often appears as physical complaints — headaches, fatigue, digestive distress — than as verbalised emotional pain [DSM-5-TR 2022].
Bipolar disorder and cognitive models Beginner
Bipolar disorder involves dramatic mood swings. A person cycles between deep depression and mania — a state of abnormally elevated mood, racing thoughts, impulsive behaviour, grandiosity, and a reduced need for sleep. During a manic episode a person might spend recklessly, launch grandiose projects, or go days without sleeping, full of restless energy.
Aaron Beck proposed that depression is held in place by negative thinking patterns. He called the core pattern the cognitive triad: a negative view of oneself, a negative view of the world, and a negative view of the future. A depressed person does not merely feel bad; they interpret events through a lens that confirms hopelessness. Cognitive behavioural therapy (CBT), which Beck developed, teaches people to identify and challenge these distorted thoughts [Beck 1976].
Martin Seligman offered a complementary account. His learned helplessness theory holds that depression takes hold when people come to believe they have no control over bad outcomes. After repeated exposure to uncontrollable negative events, a person may stop trying to change their circumstances, even when escape becomes possible. The sense of agency erodes, and with it the motivation to act.
Visual Beginner
The diagram maps the two mood-disorder spectra (unipolar and bipolar) against the explanatory frameworks — neurochemical, endocrine, genetic, and cognitive — that the rest of the unit develops.
Check your understanding Beginner
Formal definition Intermediate
The DSM-5-TR groups mood disorders into the unipolar depressive disorders and the bipolar and related disorders [DSM-5-TR 2022]. Each diagnosis is specified by a symptom threshold, a duration criterion, a clinical-significance requirement, and exclusion criteria.
Major depressive disorder (MDD). A major depressive episode requires five or more of nine symptoms during the same two-week period, with at least one symptom being either (1) depressed mood or (2) loss of interest or pleasure (anhedonia). The nine symptoms are: depressed mood most of the day; markedly diminished interest or pleasure; significant weight or appetite change; insomnia or hypersomnia; psychomotor agitation or retardation; fatigue or loss of energy; feelings of worthlessness or excessive guilt; diminished ability to think or concentrate, or indecisiveness; and recurrent thoughts of death, suicidal ideation, or a suicide attempt. The symptoms must cause clinically significant distress or impairment and must not be better explained by a medical condition or substance.
Persistent depressive disorder (dysthymia). A depressed mood for most of the day, for more days than not, for at least two years, accompanied by two or more additional depressive symptoms. It is chronic but typically milder in intensity than a major depressive episode, though major depressive episodes can be superimposed.
Disruptive mood dysregulation disorder. Diagnosed in children (ages 6-18) showing severe recurrent temper outbursts grossly out of proportion to the situation, with a persistently irritable or angry mood between outbursts, present for at least 12 months.
Bipolar I disorder. Requires at least one manic episode — a distinct period of abnormally elevated, expansive, or irritable mood and increased energy lasting at least one week (or requiring hospitalisation), with three or more symptoms such as grandiosity, decreased need for sleep, pressured speech, racing thoughts, distractibility, increased goal-directed activity, and risky behaviour. Manic episodes frequently involve psychotic features.
Bipolar II disorder. Requires at least one hypomanic episode (same symptom profile as mania but shorter — at least four days — and not severe enough to cause marked impairment or require hospitalisation, and without psychotic features) plus at least one major depressive episode. The distinction matters clinically: antidepressants given without a mood stabiliser can precipitate mania in bipolar I.
Cyclothymic disorder. Numerous periods of hypomanic symptoms and depressive symptoms (not meeting full episode criteria) for at least two years, present at least half the time.
Prevalence and course. The 12-month prevalence of MDD is approximately 7%; the lifetime prevalence is roughly 15-20%. Women are diagnosed at about twice the rate of men. Bipolar I lifetime prevalence is approximately 1%, bipolar II around 1.1%. Depression is the strongest single risk factor for suicide; roughly 15% of people with MDD make a suicide attempt, and around 3-5% die by suicide.
Key model: Beck's cognitive model and learned helplessness Intermediate
Beck's cognitive model holds that depression is maintained by the interaction of three layers of negative cognition [Beck 1976]. The cognitive triad is the surface layer: negative views of the self ("I am worthless"), the world ("Nothing goes my way"), and the future ("It will always be this way"). Beneath the triad sit automatic negative thoughts — spontaneous, plausible-seeming appraisals ("I always fail") that flash through awareness. Beneath those lie depressive schemas — deeply held core beliefs about the self, often formed in childhood, that lie dormant until activated by stress.
The model identifies characteristic cognitive distortions that warp automatic thoughts: arbitrary inference (drawing a negative conclusion without evidence), overgeneralisation (one failure becomes "I always fail"), selective abstraction (focusing on a single negative detail while ignoring positives), magnification and minimisation (exaggerating negatives, shrinking positives), and personalisation (taking responsibility for events outside one's control). CBT targets these distortions through structured identification, examination of evidence, and behavioural experiments that test the thoughts against reality.
Seligman's learned helplessness experiments provide the animal-model counterpart. Dogs exposed to inescapable shock later failed to escape shock that was escapable, lying passively instead. Abramson, Seligman, and Teasdale (1978) reformulated the theory in attributional terms: depression-prone people explain bad events with internal ("it is my fault"), stable ("it will last"), and global ("it affects everything") attributions, while explaining good events as external, unstable, and specific. This pessimistic explanatory style predicts — and is thought to partially cause — what the authors termed hopelessness depression.
The two models are complementary. Beck emphasises the content of depressive thought (the triad and schemas); Seligman emphasises the causal structure of depressive explanation (attributional style). Modern CBT integrates both, training patients to reattribute outcomes and restructure schemas.
Neurobiological correlates. The monoamine hypothesis proposes that depression reflects deficient signalling by serotonin, norepinephrine, and dopamine. Its evidence is indirect: drugs that boost monoamines (tricyclics, SSRIs, MAOIs) relieve depression, while monoamine-depleting agents can trigger it. The hypothesis is incomplete — SSRIs raise synaptic serotonin within hours, yet mood lifts only after weeks — which motivates the neurogenesis and neuroplasticity accounts developed in the master tier. The HPA axis is hyperactive in many depressed people: cortisol is elevated, and the dexamethasone suppression test fails to suppress it. Chronic stress, glucocorticoid exposure, and reduced hippocampal volume (linked to suppressed neurogenesis) form the stress-glucocorticoid-neurogenesis hypothesis. The inflammation hypothesis notes that depressed people show elevated C-reactive protein and pro-inflammatory cytokines, and that sickness behaviour overlaps clinically with depression.
Genetics. MDD heritability is approximately 37%; bipolar heritability is much higher, roughly 60-85%. Both are highly polygenic: genome-wide association studies identify many variants of tiny individual effect, captured collectively in polygenic risk scores.
Bridge. The cognitive and biological models are not rivals but two levels of the same phenomenon; this pattern appears again in the master tier, where Beck's mode theory and the rapid-acting antidepressant data build toward a unified account of how schemas, stress physiology, and synaptic plasticity reinforce one another.
Exercises Intermediate
Advanced models and treatments Master
Beck's later mode theory (Beck, 1996) refines the cognitive model. A mode is an integrated cognitive-affective-motivational-somatic subsystem that, when activated, coordinates thought, feeling, behaviour, and bodily state. In depression, a depressive mode becomes dominant and self-perpetuating: the cognitive triad, negative automatic thoughts, behavioural withdrawal, and somatic symptoms (fatigue, sleep disruption) operate as a coupled system. This reframing explains why purely intellectual challenge of a single thought often fails — the whole mode must be deactivated, which is why behavioural and experiential methods matter alongside cognitive ones.
Rumination and response styles. Nolen-Hoeksema's response styles theory identifies rumination — repetitively dwelling on one's depressive symptoms and their causes — as a process that prolongs and deepens episodes. People who ruminate recover more slowly and relapse more often than those who use distraction or problem-focused coping. This finding underwrites mindfulness-based cognitive therapy (MBCT), developed by Teasdale and colleagues, which trains metacognitive awareness — noticing thoughts as transient mental events rather than as truths. MBCT roughly halves relapse rates in people with recurrent depression.
Behavioural activation. Jacobson's behavioural activation, refined by Dimidjian and colleagues, takes a different route: rather than targeting thoughts directly, it increases contact with reinforcing activities. The influential Dimidjian et al. (2006) dismantling study found behavioural activation alone was as effective as full cognitive therapy for moderate-to-severe depression, suggesting that re-engagement with reward is a potent mechanism in its own right.
Bipolar-specific psychotherapy. Three adjunctive psychotherapies reduce relapse in bipolar disorder. Interpersonal and social rhythm therapy (IPSRT), developed by Frank, stabilises daily social rhythms — especially sleep-wake cycles — on the evidence that disrupted routines trigger episodes. Family-focused treatment (Miklowitz) psychoeducates the family and improves communication, reducing relapse and hospitalisation. Prodrome identification trains patients to recognise early warning signs (decreased need for sleep, racing thoughts) and intervene before a full episode.
Rapid-acting antidepressants and the limits of the monoamine account. Ketamine, an NMDA glutamate receptor antagonist, produces antidepressant effects within hours rather than weeks, even in treatment-resistant patients. The mechanism involves glutamate surge, downstream synaptogenesis, and brain-derived neurotrophic factor (BDNF) release. This temporal mismatch with the monoamine hypothesis shifted attention toward neuroplasticity and synaptogenesis as the proximal substrate of recovery. Psilocybin, acting primarily at 5-HT2A receptors, shows promise in treatment-resistant depression (Carhart-Harris and colleagues), with effects linked to disruption of the rigidly connected default mode network. For severely treatment-resistant cases, deep brain stimulation of the subgenual cingulate (area 25), pioneered by Mayberg, reduces symptoms in a subset of patients who have exhausted other options.
Inflammation and depression. Miller and Raison's work links depression to innate immune activation: a subset of depressed patients show elevated inflammatory markers, and inflammatory stimuli (such as interferon-alpha) can induce depressive symptoms. The overlap between sickness behaviour (lethargy, social withdrawal, anhedonia) and depression suggests a shared evolutionary circuit — a nontrivial clue that depression may, in part, be a dysregulated defensive response.
Course: recurrence kindling and the scar hypothesis. Post's kindling hypothesis holds that each depressive episode lowers the threshold for the next, so that over time episodes become more frequent, more spontaneous, and less tied to external stressors. The scar hypothesis adds that episodes themselves leave residual cognitive and interpersonal damage. Both frameworks elevate the clinical priority of preventing recurrence, not just resolving the index episode. Early adversity — particularly childhood maltreatment — is a potent risk factor, plausibly through epigenetic modification of stress-response genes (such as the glucocorticoid receptor regulator FKBP5) that durably sensitises the HPA axis.
Cultural variation. Depression does not present identically everywhere. Somatisation — the expression of distress through bodily complaints — predominates in many non-Western settings, leading to under-detection when criteria assume emotional self-report. Taijin kyofusho, a Japanese condition centred on fear of offending or discomforting others, resembles but is not identical to social anxiety and illustrates how the same distress is shaped by culturally specific concerns.
Synthesis. The cognitive, behavioural, neuroplastic, inflammatory, and kindling accounts are convergent rather than competing: stress sensitises the HPA axis and inflames the brain, erodes hippocampal plasticity, primes the depressive mode and its schemas, and — through kindling — makes the whole circuit easier to re-activate. Effective treatment intervenes at multiple levels at once, which is exactly why combined pharmacotherapy and psychotherapy outperform either alone.
Connections to other disciplines Master
Mood disorders sit at a crossroads of neuroscience, genetics, philosophy of mind, and public health. The monoamine and neuroplasticity accounts link this unit to neuroscience (29.02) and to the physiology of stress and the HPA axis. The polygenic and heritability findings connect to behaviour genetics and to the broader question of how genes and environment interact across development.
The cognitive models of Beck and Seligman connect to learning theory and conditioning (the learned helplessness animal model descends directly from operant-conditioning research) and to the study of attribution and judgment under uncertainty. The efficacy of CBT, behavioural activation, MBCT, and the bipolar-specific psychotherapies builds toward the therapy and treatment unit (29.10.01), where the common-factors versus specific-ingredients debate is taken up in full.
The cultural-variation material connects to cross-cultural and indigenous psychology (29.12), raising the philosophical question of whether depression is a natural kind or a culturally shaped category — a question continuous with the diagnostic-validity debates of the preceding unit (29.09.01). The suicide-risk data connects to health and medicine, and the inflammation and kindling findings connect to immunology and to the developmental neuroscience of early adversity.
Historical and philosophical context Master
The modern distinction between unipolar depression and bipolar disorder is younger than it appears. Through much of the twentieth century the prevailing framework was manic-depressive illness, a broad category that Kraepelin delineated in the late nineteenth century alongside dementia praecox (later schizophrenia). Kraepelin's division — separating disorders by course and outcome — shaped psychiatric taxonomy for a century. The split between unipolar and bipolar mood disorders was formalised only in the 1960s and 1970s (Leonhard, Angst, Winokur), on the evidence that unipolar depression and bipolar illness differ in heredity, course, and treatment response [Gleitman 2011].
Beck's cognitive model emerged in the 1960s against the dominance of psychoanalysis. Trained as a psychoanalyst, Beck initially sought to validate depressive hostility theories empirically; his data led him away from psychoanalysis and toward a model in which distorted cognition, not unconscious conflict, was the maintaining factor. Cognitive Therapy and the Emotional Disorders (1976) laid out the framework that would, after controlled-trial validation, become the most empirically supported psychotherapy for depression [Beck 1976].
Seligman's learned helplessness originated in 1967 experiments that were, by his own account, serendipitous — the dogs' passivity was unexpected. The 1978 reformulation with Abramson and Teasdale was a response to criticism that the original model conflated helplessness with hopelessness and could not explain individual differences. This shift toward attributional style fed Seligman's later positive psychology programme, which reframed pessimistic explanatory style as a modifiable risk factor.
Philosophically, mood disorders press on the question of whether mental illness is best understood as a brain disease, a disorder of meaning, or both. The depression-as-inflammation and kindling findings lend weight to the disease model; the efficacy of cognitive restructuring and the cultural variability of presentation lend weight to the meaning model. The honest position is that both are partial, and that the biopsychosocial framing — though often invoked glibly — is the only one that does not distort the evidence.
Bibliography Master
American Psychiatric Association. (2022). Diagnostic and Statistical Manual of Mental Disorders (5th ed., text revision). Author.
Beck, A. T. (1976). Cognitive Therapy and the Emotional Disorders. International Universities Press.
Beck, A. T., Rush, A. J., Shaw, B. F., & Emery, G. (1979). Cognitive Therapy of Depression. Guilford Press.
Abramson, L. Y., Seligman, M. E. P., & Teasdale, J. D. (1978). Learned helplessness in humans: Critique and reformulation. Journal of Abnormal Psychology, 87(1), 49-74.
Seligman, M. E. P. (1972). Learned helplessness. Annual Review of Medicine, 23, 407-412.
Post, R. M. (1992). Transduction of psychosocial stress into the neurobiology of recurrent affective disorder. American Journal of Psychiatry, 149(8), 999-1010.
Nolen-Hoeksema, S. (1991). Responses to depression and their effects on the duration of depressive episodes. Journal of Abnormal Psychology, 100(4), 569-582.
Teasdale, J. D., Segal, Z. V., Williams, J. M. G., Ridgeway, V. A., Soulsby, J. M., & Lau, M. A. (2000). Prevention of relapse/recurrence in major depression by mindfulness-based cognitive therapy. Journal of Consulting and Clinical Psychology, 68(4), 615-623.
Dimidjian, S., Hollon, S. D., Dobson, K. S., Schmaling, K. B., Kohlenberg, R. J., Addis, M. E., et al. (2006). Randomized trial of behavioral activation, cognitive therapy, and antidepressant medication in the acute treatment of adults with major depression. Journal of Consulting and Clinical Psychology, 74(4), 658-670.
Frank, E. (2005). Treating Bipolar Disorder: A Clinician's Guide to Interpersonal and Social Rhythm Therapy. Guilford Press.
Miklowitz, D. J., George, E. L., Richards, J. A., Simoneau, T. L., & Suddath, R. L. (2003). A randomized study of family-focused psychoeducation and pharmacotherapy in the outpatient management of bipolar disorder. Archives of General Psychiatry, 60(9), 904-912.
Mayberg, H. S., Lozano, A. M., Voon, V., McNeely, H. E., Seminowicz, D., Hamani, C., et al. (2005). Deep brain stimulation for treatment-resistant depression. Neuron, 45(5), 651-660.
Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., et al. (2016). Psilocybin with psychological support for treatment-resistant depression. The Lancet Psychiatry, 3(7), 619-627.
Miller, A. H., & Raison, C. L. (2016). The role of inflammation in depression: From evolutionary imperative to modern treatment target. Nature Reviews Immunology, 16(1), 22-34.
Gleitman, H., Gross, J., & Reisberg, D. (2011). Psychology (8th ed.). W. W. Norton.
Myers, D. G., & DeWall, C. N. (2021). Psychology (13th ed.). Worth Publishers.